Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azirax is an oral macrolide antibiotic containing azithromycin, manufactured and distributed by Rax Health Care. It is a small molecule that functions by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting RNA-dependent protein synthesis and preventing bacterial growth. Azirax is indicated for the treatment of various bacterial infections, including respiratory tract infections (bronchitis, pneumonia), ear and throat infections, sinusitis, skin and soft tissue infections, typhoid fever, and sexually transmitted diseases such as gonorrhea and chlamydia. It is typically administered as a 250mg or 500mg tablet once daily due to its extensive tissue distribution and long terminal half-life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azirax.